NovoCure (NVCR) Gains from Sales and Divestitures (2018 - 2019)
NovoCure recorded quarterly Gains from Sales and Divestitures of $723554.0 in Q2 2019, up 84.96% quarter-over-quarter from $391191.0 in Q1 2019, and up 31.46% year-over-year from $550418.0 in Q2 2018.
NovoCure's Gains from Sales and Divestitures history runs 2 years deep, the most recent figure standing at $723554.0 for Q2 2019.
- In Q2 2019, Gains from Sales and Divestitures rose 31.46% year-over-year to $723554.0; the TTM figure through Jun 2019 stood at $723554.0 (up 31.46% YoY), while the FY2018 annual figure was $556563.0, changed N/A from the prior year.
- Gains from Sales and Divestitures came in at $723554.0 for Q2 2019 at NovoCure, up from $391191.0 in the prior quarter.
- In the past five years, Gains from Sales and Divestitures ranged from a high of $723554.0 in Q2 2019 to a low of $256578.0 in Q1 2018.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Abbott Laboratories | 152.82 Bn | 146.17 Bn | 6.27 Bn |
| 2 | Stryker | 115.07 Bn | 112.19 Bn | 3.81 Bn |
| 3 | Medtronic | 95.25 Bn | 87.08 Bn | 5.76 Bn |
| 4 | Boston Scientific | 71.38 Bn | 70.17 Bn | 3.61 Bn |
| 5 | Edwards Lifesciences | 51.08 Bn | 47.41 Bn | 1.29 Bn |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn |
| 7 | Dexcom | 28.84 Bn | 27.72 Bn | 750.30 Mn |
| 8 | GE HealthCare Technologies | 28.56 Bn | 26.49 Bn | 1.98 Bn |
| 9 | Steris | 20.71 Bn | 20.30 Bn | 697.10 Mn |
| 10 | NovoCure | 1.90 Bn | 1.47 Bn | 135.13 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2019 | 723,554.00 |
| Jun 30, 2019 | 723,554.00 |
| Mar 31, 2019 | 391,191.00 |
| Mar 31, 2019 | 391,191.00 |
| Dec 31, 2018 | 556,563.00 |
| Dec 31, 2018 | 556,563.00 |
| Sep 30, 2018 | 550,418.00 |
| Sep 30, 2018 | 550,418.00 |
| Jun 30, 2018 | 550,418.00 |
| Jun 30, 2018 | 550,418.00 |
| Mar 31, 2018 | 256,578.00 |
| Mar 31, 2018 | 256,578.00 |